Media coverage about BioSpecifics Technologies (NASDAQ:BSTC) has been trending positive recently, Accern reports. Accern rates the sentiment of news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. BioSpecifics Technologies earned a daily sentiment score of 0.34 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 45.899685555857 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the media stories that may have effected Accern Sentiment’s scoring:
- Madrigal Pharmaceuticals (MDGL) Soars: Stock Adds 6.5% in Session (finance.yahoo.com)
- Zacks: BioSpecifics Technologies Corp. (BSTC) Given $65.00 Consensus Price Target by Analysts (americanbankingnews.com)
- BioSpecifics Technologies (BSTC) Lifted to Buy at Zacks Investment Research (americanbankingnews.com)
- New Research: Key Drivers of Growth for CNB Financial, Akebia Therapeutics, Mesoblast, 21Vianet Group, Old Line Bancshares, and BioSpecifics Technologies — Factors of Influence, Major Initiatives and Sustained Production (finance.yahoo.com)
Shares of BSTC stock traded up $0.73 during mid-day trading on Wednesday, reaching $43.40. 21,646 shares of the company’s stock were exchanged, compared to its average volume of 29,206. The company has a market cap of $307.48, a price-to-earnings ratio of 28.00 and a beta of 1.55. BioSpecifics Technologies has a fifty-two week low of $38.05 and a fifty-two week high of $58.79.
COPYRIGHT VIOLATION NOTICE: This news story was first published by BBNS and is the sole property of of BBNS. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of U.S. & international copyright legislation. The original version of this news story can be viewed at https://baseballnewssource.com/2018/03/21/biospecifics-technologies-bstc-earning-favorable-press-coverage-analysis-finds/1923454.html.
BioSpecifics Technologies Company Profile
BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development.
Receive News & Ratings for BioSpecifics Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies and related companies with MarketBeat.com's FREE daily email newsletter.